Product
Gefitinib + BKM120
1 clinical trial
2 indications
Indication
Solid TumorsIndication
NSCLCClinical trial
A Phase Ib Trial of Gefitinib (EGFR Tyrosine Kinase Inhibitor, Iressa™) in Combination With BKM120, an Oral Pan-class I PI3K Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFRStatus: Completed, Estimated PCD: 2016-02-22